Liraglutide Reconstitution Calculator

Liraglutide has a high propensity to form amyloid‑like fibrils, a specific type of aggregation where the molecule’s higher‑order structure is perturbed, characterised by a β‑sheet enrichment. In the FDA‑approved 6 mg/mL liquid formulation, this risk is minimised through precise pH control and the presence of proprietary stabilisers. Your calculator will faithfully compute concentrations from lyophilised powder, but if you reconstitute to a concentration above ~2 mg/mL without these stabilisers, you risk the peptide precipitating into visible fibrils. This is a real example: a 6 mg/mL test solution of liraglutide was specifically used in an assay to prepare fibrils for research. Always reconstitute research‑grade liraglutide powder to a final concentration ≤2 mg/mL to avoid fibrillation; the calculator cannot warn you about this.

Your calculator treats all peptides as linear, water‑soluble molecules. However, liraglutide is a synthetic acylated analogue in which a C‑16 fatty acid chain (palmitic acid) is attached to lysine at position 26 via a glutamic acid spacer, and lysine at position 34 is substituted with arginine. This fatty acid side chain dramatically reduces water solubility at low pH (≤ 0.8 mg/mL at pH 2.5) and makes the peptide behave like a self‑assembling molecule that forms heptamers in solution. If your calculator suggests a BAC volume that would give a concentration above 5 mg/mL for a small vial, the fatty acid may not fully dissolve in pure water, leading to a cloudy solution. The calculator is blind to this chemistry.

The calculator’s “Doses per vial” is a pure mathematical count based on the entered mg dose. For liraglutide, the once‑daily regimen is a core pharmacological property. In clinical use, the starting dose is 0.6 mg once daily for one week, typically increased in 0.6 mg increments to a target of 1.2‑1.8 mg per day for diabetes (Victoza) or up to 3.0 mg per day for obesity (Saxenda). If a researcher, accustomed to once‑weekly peptides, sees “7 doses per vial” in the calculator, they might assume the vial will last 7 weeks. In reality, with daily injections, it lasts only 7 days. The calculator cannot know which dosing schedule applies; you must manually adjust your expectations based on liraglutide’s distinct once‑daily pharmacology.

The commercial formulation of liraglutide (Victoza, Saxenda) is a ready‑to‑use, clear, colourless 3 mL pre‑filled pen containing 18 mg of liraglutide at a concentration of 6 mg/mL. At this concentration, 0.6 mg = 0.1 mL = 10 units on a U‑100 syringe, and 1.2 mg = 20 units, etc. Your calculator is designed for lyophilised powder, not pre‑mixed liquid pens. If a researcher obtains bulk lyophilised liraglutide powder and lets the calculator recommend a “Best” match that uses, for example, 1 mL of BAC water for a 6 mg vial (giving 6 mg/mL), they will exactly match the approved 6 mg/mL concentration. However, the calculator’s quality ranking (Best/Good/Usable) cannot account for the fact that this specific concentration was scientifically validated to balance efficacy, stability, and injection volume. Your calculator treats 6 mg/mL as just another concentration; it does not know that 6 mg/mL is the clinically established standard.

Most peptides your calculator handles are used in 0.1‑1 mg daily doses. Liraglutide’s obesity dose of 3 mg per day is 10‑30 times higher. For a 60 mg vial, 3 mg per day yields only 20 “Doses per vial”. This means a single vial lasts less than three weeks at the maximum dose. Furthermore, at 6 mg/mL, a 3 mg dose requires drawing 0.5 mL (50 units) of solution on a U‑100 syringe. This is a relatively large volume for a subcutaneous injection and is near the upper limit of what a 1 mL syringe can comfortably hold. Your calculator will correctly display this volume, but it cannot warn you that repeated 0.5 mL injections may cause more injection‑site discomfort and require rotation among multiple sites (thigh, abdomen, upper arm) more frequently than with smaller‑volume peptides. The high mass dose is a fundamental property of liraglutide that your calculator’s interface was not originally designed to emphasise.